Heregulin induces resistance to lapatinib-mediated growth inhibition of HER2-amplified cancer cells

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Downregulation of HER3 by a Novel Antisense Oligonucleotide, EZN-3920, Improves the Antitumor Activity of EGFR and HER2 Tyrosine Kinase Inhibitors in Animal Models

(2013) Y. Wu et al.   MOLECULAR CANCER THERAPEUTICS

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function

(2012) J. T. Garrett et al.   CLINICAL CANCER RESEARCH

CIN85 phosphorylation is essential for EGFR ubiquitination and sorting into multivesicular bodies

(2012) Barbara Schroeder et al.   MOLECULAR BIOLOGY OF THE CELL

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

(2011) S. Iqbal et al.   ANNALS OF ONCOLOGY

Upregulation of cancer-associated myofibroblasts by TGF-β from scirrhous gastric carcinoma cells

(2011) Y Fuyuhiro et al.   BRITISH JOURNAL OF CANCER

Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers

(2011) Timothy R. Wilson et al.   CANCER CELL

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase

(2011) J. T. Garrett et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target

(2010) F. De Vita et al.   CANCER TREATMENT REVIEWS

Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo

(2010) Z. A. Wainberg et al.   CLINICAL CANCER RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

(2010) Fumin Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer

(2009) Xiu Li Zhang et al.   WORLD JOURNAL OF SURGERY

The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines

(2008) Jin Won Kim et al.   CANCER LETTERS

FGFR2-Amplified Gastric Cancer Cell Lines Require FGFR2 and Erbb3 Signaling for Growth and Survival

(2008) K. Kunii et al.   CANCER RESEARCH

High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer

(2008) M. Hayashi et al.   CLINICAL CANCER RESEARCH

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours

(2008) Pasi A. Jänne   LUNG CANCER

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer

(2008) David Cunningham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Signaling networks assembled by oncogenic EGFR and c-Met

(2008) A. Guo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA